LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals (LGND) invested up to $47M in AvenCell for a royalty on sales of its pipeline, including AVC-201 for AML and AVC-203 for B-cell malignancies. Funding is in four tranches tied to milestones. CEO Todd Davis highlighted AvenCell's technology and data.
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f
LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receiv
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LGND (LIGAND PHARMACEUTICALS INC). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent LGND coverage spans insider activity, corporate actions and earnings.
In the last 30 days, LGND insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.8M). The most active reporter was Reardon Andrew, CLO & Secretary, with 5 filings. 83% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential upside from royalty stream if AvenCell's therapies succeed; dilution risk from cash outlay.
The capital infusion and royalty arrangement could boost Ligand's near‑term cash flow and long‑term royalty income, supporting its earnings outlook.
The deal adds a new royalty stream from a first‑in‑class myopia treatment, potentially boosting Ligand's revenue outlook.
A director's insider sale may signal limited confidence in near‑term performance.
Insider sale by a senior officer may signal reduced confidence, potentially pressuring the stock short term.
AlphAI scores every news story that mentions LGND with an AI model for sentiment and relevance, and aggregates insider trades from LIGAND PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ligand Pharmaceuticals (LGND) invested up to $47M in AvenCell for a royalty on sales of its pipeline, including AVC-201 for AML and AVC-203 for B-cell malignancies. Funding is in four tranches tied to milestones. CEO Todd Davis highlighted AvenCell's technology and data.
2 min readLIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f
1 min readLIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receiv
2 min readZimmermann Martine sold 1,200 shares of LIGAND PHARMACEUTICALS INC (LGND) at $285.00 ($0.34M total) on 2026-09-10.
1 min readReardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $286.09 ($283.99–$288.98, $1.43M total) across 5 trades on 2026-09-03 under a Rule 10b5-1 trading plan.
1 min readLigand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.
3 min readEspinoza Octavio (Chief Financial Officer) sold 31,641 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.06 ($9.24M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
1 min readHaas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.
1 min readLigand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.
6 min readLigand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.
7 min read
